News | August 02, 2021
Granules India earmarks Rs 400 crore as Capex for FY 22
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
Turnover of API division of ISLL stood at Rs 856.58 crore
WHO prequalification enables the procurement of ROTAVAC 5D by UN agencies namely UNICEF and PAHO
Price band in the range of Rs 933 to Rs 954
The group now has 320 approvals and has so far filed over 400 ANDAs
The company posted net profit of Rs.89.20 crores for the period ended June 30, 2020.
Winlevi has been approved by the United States FDA as a novel drug with a unique mechanism of action for the topical treatment of acne in patients 12 years and older
The company has decided to transfer our rights in relation to the lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited
The company is confident of commencing production at both Mahad and Chiplun units soon
ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses
Subscribe To Our Newsletter & Stay Updated
